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Abstract Dacarbazine (Dac) is one of the most com-
monly used chemotherapy drugs for treating various can-
cers. However, its poor water solubility, short half-life in
blood circulation, low response rate and high side effect
limit its application. This study aimed to improve the drug
solubility and prolong drug release by developing nanos-
tructured lipid carriers (NLCs) for Dac delivery. The NLC
and Dac-encapsulated NLC were synthesized with precirol
ATO 5 and isopropyl myristate as lipids, tocopheryl
polyethylene glycol succinate, soybean lecithin and Kol-
liphor P 188 as co-surfactants. The NLCs with controlled
size were achieved using high shear dispersion following
solidification of oil-in-water emulsion. For Dac encapsu-
lation, the smallest NLC with 155 ± 10 nm in size,
0.2 ± 0.01 polydispersion index and -43.4 ± 2 mV zeta
potential was selected. The resultant DLC-Dac possessed
size, polydispersion index and zeta potential of 190 ± 10,
0.2 ± 0.01, and -43.5 ± 1.2, respectively. The drug
encapsulation efficiency and drug loading were 98.5 % and
14 %, respectively. In vitro drug release study showed a
biphasic pattern, with 50 % released in the first 2 h, and the
remaining released sustainably for up to 30 h. This is the
first report on the development of NLC for Dac delivery,
implying that NLC could be a new potential candidate as
drug carrier to improve the therapeutic profile of Dac.
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Introduction
Dacarbazine (Dac), a highly lipid-soluble and light-sen-
sitive agent chemically known as 5-(3,3-dimethyl-1-tri-
azenyl) imidazole-4-carboxamide, is an antineoplastic
drug that has been used to treat various cancers [1]. It is
the only US Food and Drug Administration (FDA)-ap-
proved chemotherapeutic agent for treating wild-type
melanoma, a skin cancer that accounts for the vast
majority of skin cancer deaths [2, 3]. It is the most active
single agent currently used for treating metastatic mela-
noma [4]. Over the last decades, the death rate has been
increasing faster than most other types of cancer [5, 6]. At
least a third of the patients with early-stage melanoma
will develop metastases, for which the prognosis is dis-
mal. Presently, no treatment can prolong the overall sur-
vival of the disease.
The oral adsorption of Dac is very low [7]. It is
metabolized in the liver to an alkylating agent (dia-
zomethane) that destroys cancer cells [8, 9], although dif-
ferent mechanism of Dac-toxicity was also suggested [10].
The only available formulation for clinical use is delivered
through intravenous injection. After injection at
2.6–6.8 mg/body weight, the plasma concentration of the
drug reached 6 lg/mL with half-life around 41 min [11]. A
single-dose of 850–1000 mg/m [2] administered once
every 3 weeks was referenced as standard therapy with
response rate of 13–20 % of patients [12–14]. The effect
could only last for 3–6 months as the melanoma cells
develop resistance to drug-induced apoptosis and aberrant
survival pathways during progression [15]. Like other
chemotherapeutical agents, Dac also causes side effect by
killing normal dividing cells. There is an imperative need
for new Dac formulations that could extend the drug half-
life in vivo while also achieving higher tolerable dose.
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Previous studies have demonstrated that encapsulation
of therapeutic agents in nanoparticles can improve their
stability, bioavailability, pharmacokinetics and safety. It
has been demonstrated that nanoformulation of Dac such as
nanoemulsion, cubosomes and methoxy poly nanoparticles
can prolong the shelf-life, enhance therapeutic efficiency
and reduce side effect [16–19]. However, these formula-
tions showed relatively low drug encapsulation efficiency
and drug loading.
To this end, nanostructured lipid carrier (NLC) has
emerged as a promising alternative. Being the second
generation of solid lipid nanoparticles and made of a mix-
ture of solid and liquid lipids, NLC contains highly unor-
dered structures that increase the capacity for drug loading
while significantly reducing the water content in the final
formulation [20]. NLC remains solid at room and body
temperature [21]. The production of NLC is of low cost with
ease for scaling up [22]. Accordingly, NLCs have been
investigated for drug delivery through different routes
including oral, pulmonary intravenous injection, nose-to-
brain, and dermal and ocular applications [23–26]. How-
ever, there has been no report on application of NLCs for
Dac delivery. This study aimed to improve the drug solu-
bility and prolong drug release by developing nanostruc-
tured lipid carriers (NLCs) for Dac delivery. NLCs were
synthesized and studied for Dac encapsulation efficiency,
drug loading, in vitro drug release, and stability during
storage. This study suggests that the NLC developed in this
study is a potential candidate for developing new formula-
tion of Dac for improving the therapeutic profile of the drug.
Materials and methods
Materials
Dacarbazine (Dac), stearylamine (SA), D-a-tocopheryl
polyethylene glycol succinate (TPGS), isopropyl myristate
(IPM), Kolliphor P 188, acetone and ethanol ware pur-
chased from Sigma Aldrich (Gillingham, Dorset, UK). Pre-
cirol ATO-5 and medium-chain triglycerides (MCT) were
obtained from Gattefosse´ (Saint Priest Ce´dex, France).
Glycerylbehenate (GB) was supplied by Fisher Scientific
(Loughborough, UK). Soybean lecithin (SL) was obtained
from Cuisine Innovation (Dijon, France). Double-distilled
water was collected in the laboratory from Millipore-Q
Gradient A10TM ultra-pure water system (Millipore, France).
Formulation and preparation of NLCs
and NLC-Dac
Three solid lipid and liquid lipid matrices were chosen to
prepare NLCs (as shown in Table 1). The preparation
involved oil-in-water emulsion, evaporation and solidification
followed by high shear dispersion (HSD). The solid lipid,
liquid lipid and emulsifiers were mixed with 12.5 mL of
organic solvents (equal volume of acetone and ethanol) at
temperature 5 Cabove theirmeltingpoint.The emulsionwas
made by adding the oil phase drop-wise to an equal volume of
aqueous phase, which contained nonionic surfactant kol-
liphor P 188 (1–3 %) and was heated at the same tempera-
ture. The mixture was stirred for 4 h at 400 rpm using a
magnetic stirrer, and then solidified at 0 Covernight. Finally,
the solution was subjected to HSD with a homogenizer (T25
digital Ultra-Turrax, IKA, UK) at 10,000–15,000 rpm for up
to 40 min. The same procedure was used to achieve NLC-
Dac, where 35 mg of Dac was added to the oil phase.
Dynamic light scattering (DLS) assay
DLS is concerned with the measurement of particles size
and dispersity in a suspension. NLCs and NLC-Dac
preparations were measured with a Malvern Zetasizer
(Zetasizer Nanosizer S; Malvern Instruments Ltd,
Worcestershire, UK) at 25 C under a fixed angle of 90 as
described previously [27]. The measurements were
obtained at 633 nm with a 4-m He–Ne laser. To give an
average value and standard deviation for the particle size
and polydisperse index (PDI), three different batches for
each formula were analyzed five times (run). Prior to the
measurement, all the samples were diluted with double-
distilled water to a suitable scattering intensity.
Zeta potential (ZP) assay
The electro-kinetic potential for particles in colloidal sys-
tem is referred to zeta potential, indicating the level of
repulsion between adjacent particles in solution. The
potential difference between the dispersion medium fluid
and the surface of the dispersed particle is a reflection of
the stability of colloidal dispersions. The samples were
diluted with double-distilled water and injected into a
Zetasizer (Malvern Instruments Ltd, Worcestershire, UK).
Five cycles of measurements were taken to derive an
average zeta potential for each sample.
Transmission electron microscopy (TEM)
The structure and morphology of the NLCs were studied by
TEM. NLC preparations were diluted with double-distilled
water. A droplet of each sample was applied to a copper
grid coated with carbon film and air-dried. The grid was
then stained with 2 % (w/v) phosphotungstic acid (PTA)
solution and dried under room temperature. The particles
were examined using TEM (CM20, Philips) at an operating
voltage of 200 kV.
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Assessment of Dac encapsulation efficiency
and loading capacity
According to previous study, Dac can be detected with UV
spectrometer at the wavelength of 330 nm [16]. Using this
method, a standard curve for Dac detection was estab-
lished. Dac was dissolved in acetone 10–100 lg/mL and
analyzed by UV spectrometry (Double Beam UV–VIS,
UV-2100 Shimadzu, Japan). The standard curve had a
regression equation of y = 0.2338x - 0.1896 with
R2 = 0.9605. The preparation of NLC-Dac was cen-
trifuged at 12,500 rpm, 4 C for 45 min (Fresco17
Microcentrifuges, Thermo scientific, UK). The free drug in
the supernatant was detected using UV spectrometer and
the concentration was calculated according to the regres-
sion equation for the Dac standard curve. The encapsula-
tion efficiency (EF) and drug loading (DL) percentage were
derived from the following equations [28]:
EE% ¼ W1 W2=W1  100
DL% ¼ W1 W2=W3  100;
whereW1 amount of drug added in the NLC,W2 amount of
un-entrapped drug, W3 amount of the lipids added.
In vitro drug release study
The preparation of NLC-Dac was diluted at 10 % with PBS
(pH = 7.4) and incubated at 37 C in a capped centrifu-
gation tube. At intervals of 0–30 h, the solution was cen-
trifuged at 12,500 rpm, 4 C for 45 min (Fresco17
Microcentrifuges, Thermo scientific, UK). The supernatant
was then taken for analysis of free drug using UV spec-
trometer. The concentration of Dac in the supernatant was
calculated according to the regression equation of the Dac
standard curve. The drug released from NLC was expres-
sed as the percentage of total amount of drug in the
solution.
Powder X-ray diffraction (PXRD) assay
PXRD was used to determine the crystalline structure in
the NLC samples. The NLC and NLC-Dac preparations
were freeze-dried to obtain dried product and then sub-
jected to PXRD analysis. The samples were fast frozen
under -45 C in a deep-freezer overnight. Next day, they
were moved into an Edwards Modulyo K4 Freeze Dryer
(Thermo Electron Corporation, UK). After 48 h, the NLC
and NLC-Dac powders were collected and analyzed using
an X-ray Diffractometer (D5005, Siemens, UK). The
samples were pressed to a slit at 2, 2 and 1 mm and
scanned at 40 kV, 40 mA, 0.02/sec at diffraction angle of
2h for 1 h 6 min under 10–90 C.
Statistical analysis
All experiments were performed at least three times and
one of the representative experiment data was presented in
each figure. The mean values of three replicates were
expressed with standard deviation (mean ± SD). One-way
ANOVA was performed using Minitab 16 software to
determine significance of comparisons. Significant differ-
ence (P value B 0.05) was indicated by asterisk.
Results and discussion
Optimization of NLC synthesis
In order to achieve NLCs with desirable characteristics, the
components of lipids and the synthesis parameters were
optimized. A total of 24 preparations were designed to
allow optimizing the lipid matrix, surfactant concentration
and the HSD time and speed. As judged by PS and PDI of
the NLCs, the best results were achieved with 1 % of
surfactant and a sheer speed of 15,000 rpm for 30 min for
synthesis of all the NLCs. The smallest NLC of 155 nm
was achieved with the formulation NLC/PI (Fig. 1a,
bluebars), whilst the size of the formulation NLC/SI and
NLC-GM was significantly larger (compare red and green
bars with blue bars). Therefore, only NLC/PI was taken for
further analysis. The increase of surfactant concentration
from 1 to 3 % was associated with a significant increase in
PS (Fig. 1a, compare blue bars). The increase of HSD time
to 30 min resulted in a decrease in the PS and PDI of
Table 1 Components of the
NLC preparations
Formulation Solid lipid (mg) Liquid lipid (mg) Emulsifier (mg) Surfactant (%)
SA GB Precirol ATO5 IPM MCT SL TPGS Kolliphor P 188
NLC/SI 180 60 30 30 1–3
NLC/GM 180 60 30 30 1–3
NLC/PI 180 60 30 30 1–3
NLC/SI NLC made of lipids stearylamine (SA) and isopropyl myristate, NLC/GM NLC made of lipids
glyceryl behenate (GB) and medium-chain triglycerides (MCT), NLC/PI NLC made of lipids precirol ATO-
5 and isopropyl myristate (IPM), SL soybean lecithin, TPGS D-a-tocopheryl polyethylene glycol succinate
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NLCs, whilst when the time exceeded 30 min, a reverse
effect in PS and PDI occurred (Fig. 1b, c). The same was
true when the speed exceeded 15000 rpm (data not shown).
Therefore, to prepare NLC/PI for further study, these
optimal parameters were used.
The commonly used method for NLC synthesis involves
oil-in-water emulsion, homogenization and solidification,
which allows NLCs to disperse in an aqueous phase and the
inner oil phase to solidify [24, 29, 30]. For different pur-
poses modification(s) may be needed to achieve optimum
preparations.
A modification has been made in this study to perform
HSD after solidification. It was evident that the particle
size can be controlled by the speed and time of the HSD.
The failure of achieving any particles before solidification
suggests that particles were formed during solidification.
The application of HSD will disrupt the agglomerates of
the particles, which formed possibly due to hydrophobic
interaction, and also stabilize the particles by thoroughly
remixing them with surfactant. The lowest particle size and
PDI achieved after optimization of HSD speed and time
indicated that sufficient dispersion energy was achieved
and was well distributed within the solution for disruption
of particle aggregates. Further increase of the HSD speed
and time could result in a further reduction of PS, and
consequently an increase in re-aggregation due to high
inter-particle interaction force between small particles.
Characteristics of NLC/PI and NLC/PI-Dac
The NLCs were diluted with distilled water and character-
ized for PS, PDI and ZP. As shown in Table 2, NLC/PI
exhibited a PS, PDI and ZP of 155 ± 10 nm, 0.2 ± 0.1, and
-43.4 ± 2.0, respectively. As comparison, NLC/PI-Dac
was larger with no change in PDI and little change in ZP.
Both NLC/PI and NLC/PI-Dac showed a spherical shape
as observed under TEM, with NLC/PI being smaller than
NLC/PI-Dac (Fig. 2, compare a with b), consistent with the
results obtained by DLS measurement as shown in Table 2.
Each NLC was covered by a dark layer (Fig. 2, indicated
by black arrows outside NLCs), indicative of the presence
of surfactant and external solution on the surface. The
internal structures of the NLC/PI and NLC/PI-Dac were
very different. For NLC/PI, a large grey area (Fig. 2a,
indicated by white arrow) with several white rounded core
structures (Fig. 2a, indicated by black arrow inside NLC/
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Fig. 1 Optimization of parameters used in NLC preparations. The
optimal surfactant concentration and the speed and time of HSD were
adjusted according to their effect on PS and PDI. a Effect of
surfactant concentration on PS (black asterisks indicate significant
difference as compared with blue bar at the same surfactant
concentration; red asterisks indicate significant difference as com-
pared with blue bar at 1 % of surfactant. b Effect of HSD speed and
time on PS of NLC/PI. c Effect of HSD speed and time on PDI of
NLC/PI
Table 2 Physical properties of NLC/PI and NLC/PI-Dac
Samples PS (nm) PDI ZP (mV)
aNLC 155 ± 10 0.2 ± 0.01 -43.4 ± 2.0
aNLC-Dac 190 ± 10 0.2 ± 0.01 -43.5 ± 1.2
Each value represents the mean ± SD (n = 5)
PS particle size, PDI polydispersion index, ZP zeta potential
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lipid within the matrix of liquid lipid. For NLC/PI-Dac, a
well-defined white area (Fig. 2b, indicated by dotted white
arrow) with several irregularly shaped core structures
(Fig. 2b, indicated by black arrow inside NLC) was
observed under a shell (Fig. 2b, indicated by white arrow).
Within each core structure was a dark area (Fig. 2b, indi-
cated by dotted black arrow), indicating the encapsulation
of Dac.
The NLC/PI-Dac preparation achieved an encapsulation
efficiency of 98.5 % of the drug as determined using the
UV detection method on day 1 after synthesis (Table 3),
which was equivalent to drug loading capacity of
14 %.When stored in sealed amber colored glass vials in
the dark at 4 C, the physical properties of the NLCs with
respect to PS, PDI and EE % were stable for up to
3 months. As seen in Table 3, little change was detected
over the time of storage.
ZP is found to be important in the colloidal stability of
NPs in solution [31]. To achieve a good physical stability,
ZP greater than 30 mV is required, whilst for excellent
stability, ZP greater than 60 mV is required [31]. The
NLC/PI and NLC/PI-Dac both presented ZP greater than
40 mV, indicating a good stability of the preparations. To
achieve a good dispersion of lipid nanoparticles in aqueous
phase and good stability during storage, surfactants of low
toxicity and high stabilizing function have been commonly
used [32, 33]. The surfactants selected in the current study
are among the most commonly used surfactants in lipid
nanoparticle preparation and appeared compatible with
lipid components used in the preparation of the NLC/PI.
For preparation of NLC/SI and NLC/GM, further opti-
mizations are required to achieve desired PS and PDI.
PXRD assay was performed to characterize the crys-
tallinity of NLC/PI and NLC/PI-Dac with Dac as a refer-
ence (Fig. 3). As reported previously, the PXRD profile of
Dac presented a number of distinctive sharp peaks. Such
characteristic pattern was absent in the diffraction profile of
NLC/PI-Dac, indicating that Dac was no longer present as
crystalline form in the NLC/PI. Some sharp distinctive
peaks were also present in the PXRD profile of the NLC/PI,
but their intensity was much lower in the profile of NLC/
PI-Dac, indicating that Dac loading prevented the forma-
tion of solid lipid crystals to certain extent.
Several previous attempts have been made to develop
drug delivery vehicles for Dac to improve the therapeutic
profile of the drug [16, 18, 19, 34]. However, the low drug
encapsulation and loading efficiency present critical limi-
tations for these new formulations to achieve a real benefit.
For example, a drug encapsulation of 70 % and drug
loading of 15 lg/mg (1.5 %) were reported for methoxy
poly (ethylene glycol)-poly (lactide) nanoparticles [18]. In
comparison, the present study achieved a drug encapsula-
tion greater than 98 % and drug loading 14 %, which could
be due to the combination of the hydrophobic nature of
Precirol ATO 5 and the oily component. The high level of
drug incorporation was evidenced by DLS, TEM and
PXRD assays. NLC/PI-Dac was much larger than NLC/PI,
indicating a substantial level of drug loading. The differ-
ence in the lipid core structures and PXRD profiles
between NLC/PI and NLC/PI-Dac suggested that Dac
partially prevented the crystallization of the solid lipid,
leading to increased drug–lipid binding capacity.
Fig. 2 TEM images of NLC/PI
(a) and NLC/PI-Dac (b). The
black arrows outside the NLCs
indicate surfactant layer; the
white arrows indicate liquid
lipid matrix; the black arrows
inside the NLCs indicate
crystalised solid lipid; the dotted
white arrow in b indicates non-
crystalized solid lipid structure;
the dotted black arrow in
b indicates encapsulated Dac.
Bar scale 50 nm, magnification:
955,000
Table 3 Stability assessment of NLC/PI-Dac storage at 4 C
Time (days) PS PDI EE (%)
1 190 ± 10 0.2 ± 0.01 98.50
7 190 ± 10 0.2 ± 0 98.50
30 190 ± 10 0.2 ± 0.01 95.30
90 190 ± 10 0.2 ± 0.02 95.1
PS particle size, PDI polydispersion index, EE % encapsulation
efficiency
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The release of Dac from NLC/PI in vitro appeared to
follow a biphasic pattern. Nearly 50 % of the drug was
released from the formulation in the first 2 h, followed by a
sustainable release of the remaining drug for up to 30 h. It
has been suggested that the presence of drug on the surface
and outer shell of NLC contributes to the initial burst
release, whilst drug incorporated in deeper lipid phase
contributes to sustained release [29]. The present study
appeared to agree with this suggestion. In the first phase,
Dac could be released from the outer layer of the NLC
through a short diffusion path, whilst in the second phase
Dac could be released in a sustained manner from the
deeper liquid lipid phase and solid lipid cores through
diffusion and erosion mechanisms. A similar in vitro pro-
file for drug release from NLC containing Precirol ATO 5
was also reported previously [29, 35] (Fig. 4).
The release pattern of a drug from NLCs is determined
by the nature of lipid matrix, the ability of drug to partition
into both aqueous and lipid phases, temperature and sur-
factant concentration used to prepare the NLCs. The use of
surfactant and high temperature to melt the lipid will
increase the drug solubility in the aqueous phase. Upon
cooling, the drug will repartition into the lipid phase and
the solid lipid recrystallizes to form a solid lipid core.
TPGS has been often used as an emulsifier in preparation
of polymer nanoparticles [36]. It has also been recently
used in combination with SL in NLC preparation, resulting
in a smaller size and higher drug EE as compared with their
separate use [36, 37]. TPGS could protect the diffusion or
partition of hydrophobic drug from NLC to external phase
due to its big lipophilic alkyl tail (polyethylene glycol) and
hydrophilic polar head portion (tocopherol succinate) [37].
Potential of NLC/PI for Dac delivery
The only formulation of Dac in clinical use is given by
intravenous infusion with drug half-life less than 1 h [11].
A new formulation of Dac should prolong the drug half-life
in the blood circulation, allowing enough drug to accu-
mulate in target organ/tissue. Encapsulation of drug in
NLC could provide a solution. Although NLC/PI-Dac
developed in this study showed a relative earlier drug
release as compared with the formulation reported by Ding
et al. [15, 16], it has been demonstrated that a drug
encapsulated in NLC with a similar in vitro release profile
as NLC/PI-Dac developed in this study could reach the
brain 2 h after intravenous injection [29]. For NLC/PI-Dac,
although the drug in the outer layer of the NLCs could
diffuse into the blood circulation, the drug incorporated
inside NLC could be carried over to the side of action,
therefore improving the Dac therapeutic profile. Moreover,
it was suggested that lipid nanoparticles\200 nm could
form a monolayer on the skin and prevent the evaporation
of water from the skin. By forming a transcutaneous
hydration gradient, lipid nanoparticles could facilitate drug
to penetrate into the deeper layers of the skin [38]. Lipid-
based vehicles have been proposed for treating cutaneous
melanoma and epidermoid carcinoma through topical drug
delivery [19, 39], indicating that the NLC/PI-Dac devel-
oped could also be beneficial via topical route for which
early drug release would not potentially lead to severe
Fig. 3 PXRD pattern of Dac, NLC/PI-Dac and NLC/PI, respectively
(from bottom to top). Dac exhibits a characteristic peak at 38, while
NLC/PI exhibits characteristic peaks at 23 and 19 and the intensity
of the peaks reduced in NLC/PI-Dac. The x-axis represents the
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Fig. 4 In vitro drug release profile of Dac from NLC/PI in PBS
(pH = 7.4). The NLC/PI-Dac preparation was diluted at 10 % in PBS
and incubated at 37 C. At predetermined intervals, the release of Dac
was determined by UV detection and expressed as percentage of total
loaded amount of the drug
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systemic toxicity. This study implicates that NLC could
have the potential for drug delivery via multiple routes.
Conclusion
This is the first report on the development of NLCs for Dac
delivery. The commonly used method for NLC synthesis
has been modified as such that it involved oil-in-water
emulsion, evaporation and solidification followed by HSD
to achieve NLCs with desirable size. As compared with
some existing approaches for Dac encapsulation with dif-
ferent materials, using NLC proved beneficial in improving
the drug encapsulation and loading efficiency, prolonging
drug release, storage stability, and simplified synthesis.
This research suggests that NLC/PI is a new potential
candidate for Dac delivery to overcome the limitations of
short half-life, and low tolerant dose of the drug. Further
study will be required to assess the profile of NLC/PI-Dac
drug release and toxicity in vitro and in vivo.
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